EFOMP: Advancing SGRT through Clinical Collaboration

Building a clinical SGRT network

When LAP introduced LUNA 3D and the system received CE marking in 2024, our goal was not just to launch a new SGRT system, but to develop a solution shaped by clinical reality. This ambition is reflected in our guiding claim, "The New More in SGRT." From the very beginning, input from clinical experts has played a key role in defining the LUNA 3D system. Just two years later, more than 100 installations are in place worldwide. Collaboration with clinical users has become the driving force behind our approach. A global network of dedicated clinical partners continuously contributes feedback from daily use of LUNA 3D, ensuring that our development efforts always reflect the clinical needs of modern radiotherapy.

Insights from clinical practice

In April 2026, we hosted our LUNA 3D Clinical Partner Meeting in Valencia. Experts from university clinics and private radiotherapy centers from Belgium, Germany, and France came together to share their experiences and discuss future directions in SGRT with LAP.
Participants represented different stages of the LUNA 3D experience: some are early adopters of LUNA 3D and have known the system since its development phase, while others have just recently started using it in clinical practice. This diversity enabled a balanced discussion covering both initial implementation and long-term optimization.

Clinical impact of LUNA 3D

Clinical partners reported clear benefits in daily practice, including more efficient patient setups and improved confidence in positioning. Some centers also noted a reduction in repeat CBCT scans, leading to potentially lower imaging dose.
For complex treatments, SGRT was described asproviding additional confidence, particularly for large fields or multi-isocenter setups, where precise alignment before irradiation is critical. In this context, surface guidance can offer an additional layer of information to support clinical decision-making.
Another aspect highlighted by users was the ability to work without skin marks or tattoos. Several centers have implemented markerless workflows, which may enhance patient comfort while streamlining clinical processes. This can be particularly relevant in sensitive cases such as pediatric treatments, where reducing physical and emotional burden is an important consideration.
Across these use cases, user feedback consistently pointed to the intuitive and streamlined nature of LUNA 3D. RTTs noted that the system supports their daily work by facilitating efficient and user-friendly workflows – reflecting the guiding principle of LUNA 3D being designed to be "as easy as a laser."

Collaboration shaping the future

Beyond the exchange with LAP, one of the most valuable aspects of the meeting was the direct interaction between the clinics. Participants openly shared their experiences, discussed challenges, and exchanged practical solutions, creating a strong sense of mutual support.
We also discussed what comes next for LUNA 3D, including the upcoming update with significant new features, as well as developments such as surface-guided in vivo dosimetry, which is planned for introduction soon.
The key takeaway from Valencia is clear: progress in SGRT is not driven by technology alone, but by close collaboration with clinical experts and a strong focus on real-world application.

Author

Jens Gauthier is Executive Managing Director Healthcare at LAP.
He has been with the company for over 20 years, contributing to its growth into a global technology leader.
His focus is on advancing innovative medical solutions that improve precision and safety in radiation therapy while supporting patient-centered care.